Urinary tract infection

PathogenDx Launches Novel D3 Array Multiplexed Molecular Diagnostics Technology for Urinary Tract Infection (UTI) Pathogen Detection and Antibiotic Resistance

Retrieved on: 
Wednesday, February 7, 2024
Workflow, Patient, Safety, Pain, Running, Diagnosis, Urinary tract infection, Temperature, Sepsis, Laboratory, Data analysis, Real-time, Physician, Pyelonephritis, D3, Health, UTI, PCR

Powered by the Company's novel multiplexed molecular diagnostics technology, D3 Array™-UTI features testing in triplicate for quality assurance, with qualitative and quantitative results in the same reaction, as well as automated, cloud-based data analysis, reporting and management.

Key Points: 
  • Powered by the Company's novel multiplexed molecular diagnostics technology, D3 Array™-UTI features testing in triplicate for quality assurance, with qualitative and quantitative results in the same reaction, as well as automated, cloud-based data analysis, reporting and management.
  • "Providing a proper UTI diagnosis is a race against the clock," said PathogenDx Co-founder and CEO, Milan Patel .
  • "An individual is risking continued pain and discomfort, chronic infections, kidney infection, and in severe cases, sepsis.
  • The array is equipment agnostic, making it compatible with routine molecular instrumentation and existing workflow.

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO

Retrieved on: 
Thursday, February 1, 2024
Bachelor of Science, Growth, CFO, Therapy, Patient, KPMG, Vertex Pharmaceuticals, Regulatory affairs, Biomedical sciences, Urinary tract infection, Physics, University of Nottingham, University, Doctor of Philosophy, Senior, Clinical research

Dr Barnes has eighteen years’ early and late phase drug development and business operations leadership experience, spanning several therapeutic areas.

Key Points: 
  • Dr Barnes has eighteen years’ early and late phase drug development and business operations leadership experience, spanning several therapeutic areas.
  • He joins the Company from BerGenBio, a biotech company developing innovative drugs for oncology and serious respiratory infections, where he was COO.
  • Dr Barnes previously worked at Vertex Pharmaceuticals as Director of Regulatory Affairs where he led the strategy development of several breakthrough products.
  • With our first clinical data expected this year, the newly strengthened Executive Team will support the development and growth of our business.

Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Urinary tract infection, Chronic obstructive pulmonary disease, CFTR, Mortality, FEV1, Respiratory disease, Therapy, Disease, Patient, Enterprise, Mucus, IP Group, Cystic fibrosis, Epithelial sodium channel, Asthma, Atomic mass

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

Key Points: 
  • Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.
  • Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated.
  • Alongside the financing, Dr Rob Woodman, Partner at Panakes, joins Enterprise’s Board of Directors.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: “We have made tremendous progress to date in developing novel therapeutics for patients suffering from chronic respiratory diseases.

CRANBYCST MAX Is a Proven, Efficient Solution for Managing UTIs and Chronic Cystitis

Retrieved on: 
Thursday, February 1, 2024
Orthosiphon stamineus, Research, System, Urinary tract infection, Capsule, Female, Herbal, Health, Anatomy, Woman, Dietary supplement

FORT LAUDERDALE, Fla., Feb. 1, 2024 /PRNewswire/ -- Urinary tract infections or UTIs are a regular struggle for many individuals. While a more common affliction for female anatomy, both men and women alike struggle with the condition, many on a recurring basis. UTIs can develop due to a variety of reasons. Unsanitary bathroom habits, repeated bacterial exposure from sexual activity, and even anatomic and genetic predisposition can be culprits.

Key Points: 
  • PLAMECA's natural solution, CRANBYCYST MAX , uses safe nutraceutical ingredients to prevent conditions such as UTIs and cystitis and manage the overall health of the urinary tract.
  • "Our formula uses natural ingredients in targeted doses to address existing UTIs and guard against future incidents," explains Óscar Fernández.
  • PLAMECA's managing director adds that the use of natural phytotherapy solutions to address urinary tract health is a safe and proven solution.
  • The study went on to confirm through multiple clinical cases that long-term courses of phytotherapy have a high efficiency in managing UTIs.

Why Phytotherapy Requires Pharmaceutical Precision

Retrieved on: 
Thursday, February 1, 2024
Mineral, Plant, COVID-19, Vitamin, Knowledge, Attitude, Pregnancy, Herbal, Insomnia, Urinary tract infection, Medicine, Health, Woman, Dietary supplement

FORT LAUDERDALE, Fla., Feb. 1, 2024 /PRNewswire/ -- Pharmaceutical solutions are always treated with caution. Application and dosage are important, and individuals are well aware of the risks that come with mistreating medications. However, attitudes tend to relax when it comes to natural alternatives to medicine. Phytotherapy (the use of medicinal botanicals like plants and herbs to manage health) is often incorrectly considered a casual and unspecific support option. It is a concept that the team at PLAMECA is striving to counteract.

Key Points: 
  • Phytotherapy (the use of medicinal botanicals like plants and herbs to manage health) is often incorrectly considered a casual and unspecific support option.
  • "Phytotherapy is a powerful, safe, and effective way to manage a person's health," says PLAMECA's managing director Óscar Fernández.
  • The executive adds that the proper production of phytotherapy products is an essential first step in using them correctly.
  • From formulation to manufacturing to distribution, the company is an ideal example of how to bring pharmaceutical precision to the fast-growing field of phytotherapy.

Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY® (bexagliflozin) with TheracosBio Partnership

Retrieved on: 
Thursday, February 1, 2024
Partnership, Exercise, Patient, SGLT2, Urination, Urinary tract infection, FDA, Diet, Diabetes, Pharmacy, IPC, SUN, Female, Type 2 diabetes, Insurance, Blood pressure, Pharmacist, Pharmaceutical industry

SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies.

Key Points: 
  • SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies.
  • IPC, renowned for its commitment to supporting independent pharmacies, is set to be the first pharmaceutical wholesaler in the United States to carry and distribute BRENZAVVY.
  • BRENZAVVY, an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, presents a groundbreaking approach to diabetes care.
  • IPC members and customers will benefit from this exclusive arrangement, reinforcing IPC's commitment to expanding the range of cost-effective, clinically meaningful products available to independent pharmacies.

Volurine Utilizes D-Mannose to Safely Prevent UTIs

Retrieved on: 
Wednesday, January 31, 2024
Mannose, Bacteria, Heart, System, Urinary tract infection, Urination, Escherichia coli, Risk, Infection, UTI, Health, Genetically modified bacteria, Woman, Dietary supplement

FORT LAUDERDALE, Fla., Jan. 31, 2024 /PRNewswire/ -- Urinary tract infections or UTIs are a common bacterial infection. Health brand SYNEVIT®'s natural supplement Volurine helps manage UTIs quickly. Its key ingredient is D-mannose, which has been shown to be effective in managing one of the most common bacterial culprits in UTIs.

Key Points: 
  • Health brand SYNEVIT®'s natural supplement Volurine helps manage UTIs quickly.
  • Its key ingredient is D-mannose, which has been shown to be effective in managing one of the most common bacterial culprits in UTIs.
  • One of these is D-mannose, a natural simple sugar that functions as the key ingredient in SYENVIT®'s UTI supplement Volurine .
  • It is becoming a popular natural alternative that is a safe, effective way to prevent UTIs without the need to wait for the signs of a painful infection to appear.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse